Solid Organ Transplantation in the Era of COVID-19

doi:10.3390/books978-3-0365-6514-9

Download Url(s)

https://mdpi.com/books/pdfview/book/6743

Contributor(s)

Schuurmans, Macé M. (editor)

Hage, René (editor)

Language

English

Show full item record

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus disease 2019 (COVID-19), posing a new challenge to the medical care of solid organ transplant (SOT) recipients. Due to the relatively small number of studies in SOT recipients suffering from COVID-19, the natural course of the SARS-CoV-2 infection, optimal treatment strategies including modification of immunosuppressive therapy and the prognosis in COVID-19 in these patients is incompletely understood. The current Special Issue aimed to fill some of the knowledge gaps and highlight some recent advances in the management of SOT patients during the pandemic. The call for manuscripts had been addressed to healthcare professionals involved in SOT patient care. We welcomed comprehensive reviews, original studies, interesting case series or case reports and commentaries relating to this topic.

URI

https://directory.doabooks.org/handle/20.500.12854/98016

Keywords

SARS-CoV-2; coronavirus; immunosuppression; tacrolimus; corticosteroids; mycophenolate mofetil; hyperinflammation; cytokine storm; pandemic; transplantation; Lung Transplantation; COVID-19; Coronavirus; norovirus; treatment; hypothesis; cytokine storm syndrome; FK506; cyclosporine; myocarditis; pediatric heart transplantation; viral infection; dexamethasone; remdesivir; hemodialysis; transplant; kidney; PCR; infection; transplant recipients; inflammation; survival; n/a; solid-organ transplant; unvaccinated; lung transplantation; fibrosis; phenotype hypothesis; lung transplant recipients; immunocompromised; breakthrough infections; chronic lung allograft dysfunction; community-acquired respiratory viral infection; CLAD hypothesis